Please provide your email address to receive an email when new articles are posted on . The FDA has accepted a new drug application for CSF-1 for the treatment of presbyopia, according to a press ...

The MarketWatch News Department was not involved in the creation of this content. The launch of emerging therapies, such as LNZ100 by Lenz Therapeutics, Phentolamine Ophthalmic Solution 0.75% by ...

TearOptix, Inc., a pioneering contact lens company developing advanced solutions for patients with presbyopia, today announced the completion of a strategic corporate financing round led by investors ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. I’ve said it before: There are four stages of life.

Vuity contracts the iris sphincter muscle, constricting the pupil to improve near and intermediate visual acuity. The Food and Drug Administration (FDA) has approved the supplemental New Drug ...

- Investigational, novel eye drop candidate was assigned PDUFA goal date of October 22, 2023 PONTE VEDRA, Fla., Feb. 21, 2023 /PRNewswire/ -- Orasis Pharmaceuticals, an emerging ophthalmic ...

When people get into their 40s and beyond, their close-up vision starts to worsen. For many people, cranking up the font size on a phone or maxing out the brightness on a computer is the only way to ...

SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (LENZ) (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial biopharmaceutical company focused on the development and ...

The Myopia and Presbyopia Treatment Market is experiencing significant growth due to the increasing prevalence of vision loss from nearsightedness and age-related presbyopia. Elderly people and ageing ...

The Companies plan to file an application with the FDA in the second half of 2025. Topline data were announced from a phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) for the ...

LNZ100 shows superior efficacy and safety in presbyopia treatment, with a strong probability of FDA approval by August 2025. LNZ100 outperforms competitors Vuity and Qlosi, offering faster and greater ...